

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		Atty Docket No.: 7119US01 LIPID SYSTEM AND METHOD OF USE					
		Serial No.: 10/656,662 Applicant(s): Vikkie A. Mustad et al. Filing Date: Sept. 5, 2003 Group: Not yet assigned					
U.S. PATENT DOCUMENTS							
Exam. Init.		Patent Number	Issue/Publication Date	Patentee	Class	Subclass	Filing Date
		6,468,987	Oct. 22, 2002	DeMichele et al.			
		6,140,304	Oct. 31, 2000	Sears			
		5,952,314	Sep. 14, 1999	DeMichele et al.			
		5,922,704	Jul. 13, 1999	Bland			
		5,922,345	Jul. 13, 1999	Horrobin et al.			
		5,895,652	Apr. 20, 1999	Giampapa			
		5,780,451	Jul. 14, 1998	DeMichele et al.			
		5,763,484	Jun. 9, 1998	Horrobin			
		5,698,594	Dec. 16, 1997	Breivik et al.			
		5,656,667	Aug. 12, 1997	Breivik et al.			
		5,502,077	Mar. 26, 1996	Breivik et al.			
		5,308,832	May 3, 1994	Garleb et al.			
		5,059,622	Oct. 22, 1991	Sears			
		4,921,877	May 1, 1990	Cashmere et al.			
		4,526,902	Jul. 2, 1985	Rubin			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Exam. Init.		Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
		WO 99/62359	Dec. 9, 1999	WIPO			N/A
		JP8198749	Aug. 6, 1996	Japan Patent Office		. Y	abstract
		EP0937408	Aug. 25, 1993	European Patent Office		Y	abstract
		GB2223943	Mar. 25, 1990	United Kingdom			N/A
OTHER DOCUMENTS (Including Author, Title, Date**, Relevant pages, Place of Publication***)							
		Kato et al., <u>Effect of Alpha-Linolenic Acid on Blood Glucose, Insulin and GLUT4 Protein Content of Type 2 Diabetic Mice</u> , <i>Journal of Health Science</i> 46, 489-492 (2000).					
		Hun et al., <u>Increased Uncoupling Protein2 mRNA in White Adipose Tissue, and Decrease in Leptin, Visceral Fat, Blood Glucose, and Cholesterol in KK-A^y Mice Fed with Eicosapentaenoic and Docosahexaenoic Acids in Addition to Linolenic Acid</u> , <i>Biochemical and Biophysical Research Communications</i> 259, 85-90 (1999).					
		McManus et al., <u>A Comparison of the Effects Of n-3 Fatty Acids from Linseed Oil and Fish Oil in Well-Controlled Type II Diabetes</u> , <i>Diabetes Care</i> 19, 463-467 (1996).					
		Goh et al., <u>Effect of ω3 Fatty Acid on Plasma Lipids, Cholesterol and Lipoprotein Fatty Acid Content in NIDDM Patients</u> , <i>Diabetologia</i> 40, 45-52 (1997).					
		Nestel et al., <u>Aterial Compliance in Obese Subjects is Improved with Dietary Plant n-3 Fatty Acid from Flaxseed Oil Despite Increased LDL Oxidizability, Arteriosclerosis, Thrombosis, and Vascular Biology</u> 17, 1163-1170 (1996).					
		Simopoulos, <u>Essential Fatty Acids in Health and Chronic Disease</u> , <i>Am. J. Clin. Nutr.</i> 70 (suppl.), 560S-569S (1999).					
		Siguel, <u>Deficiencies and Abnormalities of Essential Fats in Gastrointestinal and Coronary Artery Disease</u> , <i>J. Clin. Ligand Assay</i> 23, 104-111 (2000).					

CJ

NOV 26 2003

Examiner	Date Considered
EXAMINER: Initial citation provided. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 1 of 1

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 7119US01	Serial No. 10/656,662
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Mustad, et al.	
(Use several sheets if necessary)		Filing Date 9/5/03	Group 1623

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Name	Class	Subclass	Translation (Yes No)
	WO 0211552	2/14/02				
	EP 1269859	1/2/03				
	EP 0682879	11/22/95				
	WO 0217903	3/7/03				
	WO 0112179	2/22/01				
	CN 1339262	3/13/02				
	WO 9526646	10/12/95				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>Carr</i>	DATE CONSIDERED <i>4/25</i>
-------------------------	--------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.